CXL can be used to treat infectious fungal keratitis


Corneal cross-linking (CXL) is effective in reducing the severity of infectious keratitis caused by Fusarium solani.

Corneal cross-linking (CXL) is effective in reducing the severity of infectious keratitis caused by Fusarium solani, according to a study in the Journal of Cornea and External Disease.

Dr Gustavo Galperin, Laboratorio de Investigaciones Oculares, Buenos Aires, Argentina, led an investigation on 24 rabbits innoculated with Fusarium solani in the stromata of the right cornea.

All rabbits were divided into two groups. Group 1 was treated with CXL 72 hours after inoculation and group 2, acting as control, received no treatment. In both groups all eyes were assessed preoperatively on days 0 and 3, and postoperatively on day 7. Eyes were enucleated and the corneal buttons were microbiologically and histologically examined.

Clinical scores were statistically significant between the two groups after CXL, with group 1 demonstrating a significantly lower clinical score. Group 1 had 22.45 ± 5.09 CFU/g compared with 42.5 ± 3.12 CFU/g in group 2.

Similar amounts of Fusarium hyphae and inflammatory cells were found in 3 corneal buttons from group 2. In 2 of the 3 buttons obtained from group 1 there were fewer Fusarium hyphae, inflammatory cells, and nonspecific stromal changes than in group 2.

The study results suggest that CXL could be helpful as a coadjuvant for the treatment of resistant fungal infections.

Recent Videos
Theodore Leng, MD, MS, speaks about 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema:The FARETINA-DME Study
Rishi P. Singh, MD, discussed his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
Carl C. Awh, MD, FASRS, speaks with Hattie Hayes of Ophthalmology Times Europe
Carl J. Danzig, MD
Martin Zinkernagel, MD, PhD, speaks about the ASRS sustainability expert panel
Srinivas Sai Kondapalli, MD, discusses outer retinal tubulations in lesion growth for subfoveal and non-subfoveal GA
Jennifer I. Lim, MD, FARVO, FASRS
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
© 2024 MJH Life Sciences

All rights reserved.